Evidence map›Paper›PMID 10829070›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase.

A B Satterthwaite, F Willis, P Kanchanastit, D Fruman, L C Cantley, C D Helgason, R K Humphries, C A Lowell, M Simon, M Leitges and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02446236 (Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02446236 phase1active not recruitingnot on this mapstarted 2015, after this paper: background citation

Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

TypeinterventionalSponsorHackensack Meridian HealthRan2015 to 2026Enrolled27ConditionsMantle Cell LymphomaArmsLenalidomide, Ibrutinib, Rituximab
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Editorial: Targeting Bruton Tyrosine Kinase.Frontiers in cell and developmental biology · 2022
    Article
  4. BTK, the new kid on the (oncology) block?Frontiers in oncology · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Silencing of B cell receptor signals in human naive B cells.The Journal of experimental medicine · 2002
    Article
  13. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes.Proceedings of the National Academy of Sciences of the United States of America · 2002
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

A B SatterthwaiteDepartment of Microbiology, Immunology, and Molecular Genetics, and Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095, USA.
F Willis
P Kanchanastit
D Fruman
L C Cantley
C D Helgason
R K Humphries
C A Lowell
M Simon
M Leitges
A Tarakhovsky
T F Tedder
R Lesche
H Wu
O N Witte
Howard Hughes Medical Institute · US

Funding

The Role of PI3K in Growth RegulationR01GM041890 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CANTLEY, LEWIS C. · 1990 to 2016
$4.1M
PHOSPHATDYLINOSITOL-3-P AND GROWTH REGULATIONR37GM041890 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CANTLEY, LEWIS C. · 1999 to 2008
$3.8M
MOLECULAR ANALYSIS OF B-LYMPHOCYTE RESTRICTED PROTEINSR01CA081776 · NCI · DUKE UNIVERSITY · PI TEDDER, THOMAS F · 1999 to 2002
$894k
REGULATION OF LEUKOCYTE RECIRCULATIONR01CA054464 · NCI · DUKE UNIVERSITY · PI TEDDER, THOMAS F · 1992 to 2001
$580k
THROMBIN RECEPTOR'S ROLE IN PLATELET AND MEGAKARYOCYTE BIOLOGYP01DK050267 · NIDDK · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LOWELL, CLIFFORD A · 1995 to 1999
–
REGULATION OF HUMAN LEUKOCYTE RECIRCULATIONR55CA054464 · NCI · DANA-FARBER CANCER INSTITUTE · PI TEDDER, THOMAS F · 1991 to 1991
–
NCI NIH HHS CA-54464NCI NIH HHS CA-81776NIDDK NIH HHS DK50267NIGMS NIH HHS R01 GM041890NIGMS NIH HHS R37 GM041890
6 · The paper itself

Abstract

Modifier screens have been powerful genetic tools to define signaling pathways in lower organisms. The identification of modifier loci in mice has begun to allow a similar dissection of mammalian signaling pathways. Transgenic mice (Btk(lo)) expressing 25% of endogenous levels of Bruton's tyrosine kinase (Btk) have B cell functional responses between those of wild-type and Btk(-/-) mice. We asked whether reduced dosage or complete deficiency of genes previously implicated as Btk regulators would modify the Btk(lo) phenotype. We used two independent assays of Btk-dependent B cell function. Proliferative response to B cell antigen receptor cross-linking in vitro was chosen as an example of a relatively simple, well-defined signaling system. In vivo response to type II T-independent antigens (TI-II) measures complex interactions among multiple cell types over time and may identify additional Btk pathways. All modifiers identified differentially affected these two assays, indicating that Btk mediates these processes via distinct mechanisms. Loss of Lyn, PTEN (phosphatase and tensin homolog), or SH2-containing inositol phosphatase suppressed the Btk(lo) phenotype in vitro but not in vivo, whereas CD19 and the p85alpha form of phosphoinositide 3-kinase behaved as Btk(lo) enhancers in vivo but not in vitro. Effects of Lyn, PTEN, or p85alpha haploinsufficiency were observed. Haploinsufficiency or complete deficiency of protein kinase C beta, Fyn, CD22, Galphaq, or Galpha11 had no detectable effect on the function of Btk(lo) B cells. A transgenic system creating a reduction in dosage of Btk can therefore be used to identify modifier loci that affect B cell responses and quantitatively rank their contribution to Btk-mediated processes.

Indexed as

Signal TransductionTumor Suppressor ProteinsAgammaglobulinaemia Tyrosine KinaseAnimalsAntigens, CD19B-LymphocytesMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphatidylinositol 3-KinasesPhosphoric Monoester HydrolasesProtein Kinase CProtein-Tyrosine KinasesPTEN PhosphohydrolaseAgammaglobulinaemia Tyrosine KinaseAntigens, CD19BTK protein, humanBtk protein, mouseINPPL1 protein, humanPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphatidylinositol 3-KinasesPhosphoric Monoester HydrolasesProtein Kinase CProtein-Tyrosine KinasesPTEN PhosphohydrolaseReceptors, Antigen, B-CellTumor Suppressor Proteins

Identifiers

PMID10829070
PMCPMC18703
OpenAlexW2118108045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.